Protocol H8H-MC-LAIG
A Study to Investigate the Cardiovascular Effects of Lasmiditan in Healthy Elderly Subjects
[STUDY_ID_REMOVED]   
Approval Date:19-Dec-2017 
H8H-MC-LAIG Clinical Pharmacology Protocol Page 1
LY573144Protocol H8H -MC-LAIG
A Stud y to Investigate the Cardiovascular Effects of 
Lasmiditan in Healthy  Elderly  Subjects
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of
lasmiditan (LY573144) , unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise dissem inated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Lasmiditan (LY573144)
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Clinical Pharmacology Protocol Electronically Signed and Approved by Lilly on date 
provided belo w.
Approval Date: 19-Dec-2017 GMT
H8H-MC-LAIG Clinical Pharmacology Protocol Page 2
LY573144Table of Contents
A Stud y to Investigate the Cardiovascular Effects of 
Lasmiditan in Healthy  Elderly  Subjects
Section Page
Protocol  H8H -MC-LAIG ............................................................................................................ 1
A Study  to Invest igate the Cardiovascular Effects of Lasmiditan in 
Healthy El derly  Subjects ..................................................................................................... 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 7
2. Schedule of Act ivities......................................................................................................... 9
3. Introduction ...................................................................................................................... 14
3.1. Study  Rationale ............................................................................................................ 14
3.2. Background .................................................................................................................. 14
3.3. Benefit/Risk Assessment .............................................................................................. 15
4. Object ives and Endpo ints.................................................................................................. 17
5. Study  Design ..................................................................................................................... 18
5.1. Overall Design ............................................................................................................. 18
5.2. Num ber of Participants .................................................................................................18
5.3. End of Study  Definit ion............................................................................................... 19
5.4. Scientific Rationale for Study  Design ........................................................................... 19
5.5. Justification for Dose ................................................................................................... 19
6. Study  Popul ation............................................................................................................... 20
6.1. Inclusio n Cri teria.......................................................................................................... 20
6.2. Exclusio n Cri teria........................................................................................................ 21
6.2.1. Rationale for Excl usion of Certain Study  Candidates ........................................... 22
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 22
6.3.1. Meals and Dietary  Restri ctions............................................................................. 23
6.3.2. Caffeine, Alcoho l, Tobacco, and Grapefruit ......................................................... 23
6.3.3. Activity................................................................................................................ 23
6.4. Screen Failures ............................................................................................................. 23
7. Treat ment .......................................................................................................................... 24
7.1. Treatment Administered ............................................................................................... 24
7.1.1. Packaging and Labeling ....................................................................................... 24
7.2. Method of Treatment Assignment ................................................................................ 25
7.2.1. Selection and Timing o f Doses ............................................................................. 25
H8H-MC-LAIG Clinical Pharmacology Protocol Page 3
LY5731447.3. Blinding ....................................................................................................................... 25
7.4. Dose Modificat ion........................................................................................................ 25
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 25
7.6. Treatment Compliance .................................................................................................26
7.7. Concomitant Therapy ................................................................................................... 26
7.8. Treatment after the End of the Study ............................................................................ 26
8. Discontinuati on Cri teria .................................................................................................... 27
8.1. Discontinuati on from Study  Treatm ent......................................................................... 27
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Subjects .............................................. 27
8.2. Discontinuati on from the Study .................................................................................... 27
8.3. Subjects Lost to Follow -up........................................................................................... 28
9. Study  Assessments and Procedures ................................................................................... 29
9.1. Efficacy Assessments ................................................................................................... 29
9.2. Adverse Events ............................................................................................................ 29
9.2.1. Serious Adverse Events ........................................................................................ 30
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 30
9.2.2. Com plaint Handling ............................................................................................. 31
9.3. Treatment of Overdose .................................................................................................31
9.4. Safety........................................................................................................................... 31
9.4.1. Laborator y Tests .................................................................................................. 31
9.4.2. Vital Signs ........................................................................................................... 31
9.4.2.1. Ambulatory  Blood Pressure Moni toring.......................................................... 31
9.4.3. Electrocardiograms .............................................................................................. 32
9.4.4. Safety Moni toring ................................................................................................ 32
9.4.4.1. Hepati c Safet y................................................................................................ 33
9.5. Pharmacokinet ics......................................................................................................... 33
9.5.1. Bioanalysis ........................................................................................................... 33
9.6. Pharm acodynamics ...................................................................................................... 34
9.7. Genet ics....................................................................................................................... 34
9.8. Biomarkers ................................................................................................................... 34
9.9. Heal th Economics ........................................................................................................ 34
10. Statistical Considerations and Data Analysis ..................................................................... 35
10.1. Sample Si ze Determinat ion.......................................................................................... 35
10.2. Popul ations for Analyses .............................................................................................. 35
10.2.1. Study  Parti cipant Disposit ion............................................................................... 35
10.2.2. Study  Parti cipant Characterist ics.......................................................................... 35
10.3. Statistical Analyses ...................................................................................................... 35
10.3.1. Safety Analyses .................................................................................................... 35
H8H-MC-LAIG Clinical Pharmacology Protocol Page 4
LY57314410.3.1.1. Clinical Evaluation of Safet y.......................................................................... 35
10.3.1.2. Statistical Evaluat ion of Safet y....................................................................... 36
10.3.2. Pharmacokinet ic Analyses .................................................................................... 36
10.3.2.1. Pharmacokinet ic Parameter Estimat ion........................................................... 36
10.3.2.2. Pharmacokinet ic Statistical Analysis ............................................................... 36
10.3.3. Cardi ovascular Analyses ...................................................................................... 36
10.3.3.1. Cardi ovascular Param eter Estimat ion............................................................. 36
10.3.3.2. Statistical Inference of Cardiovascular Parameters .......................................... 36
10.3.4. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 37
10.3.5. Interim Analyses .................................................................................................. 37
11. References ........................................................................................................................ 38
H8H-MC-LAIG Clinical Pharmacology Protocol Page 5
LY573144List of Tables
Table Page
Table 4.1. Object ives and Endpo ints....................................................................... 17
Table 5.1. Sequences in Study  LAIG ....................................................................... 18
Table 7.1. Treatments Administered ........................................................................ 24
H8H-MC-LAIG Clinical Pharmacology Protocol Page 6
LY573144List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 39
Appendix 2. Clinical Laboratory  Tests ........................................................................ 43
Appendix 3. Study  Governance, Regulatory , and Ethi cal Considerati ons.................... 44
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 47
Appendix 5. Blood Sam pling Summary ...................................................................... 48
H8H-MC-LAIG Clinical Pharmacology Protocol Page 7
LY5731441.Protocol Synopsis
Title of Study:
A Study to Investigate the Cardiovascular Effects of Lasmiditan i n Healthy Elderly Subjects
Rationale: 
Study H8H-MC -LAHA (LAHA) wasrecently conducted to determine the pharmacokinetics ( PK)and safety of 
lasmiditan in elderly and young healthy subjects following a single or al administration of lasmiditan 200 mg .The 
study database has been locked but the clinical study report has not been finalized. A review of preliminary data 
from the elderly cohort showed that following administration of lasmiditan 200 mg, there was atransient elevation 
in mean supine systoli c blood pressure (SBP) and diastolic blood pressure (DBP) between 60 and 90 minutes 
postdose, with a mean maximum SBP increase of 14.5 mmHg and DBP increase of 3.8 mmHg compared with 
baseline. Because the number of subjects enrolled in LAHA was based on s tatistical power to detect differences in 
PK, it was not possible to determine if the observed effects on blood pressure ( BP)were statistically significant.
Elderly  patients with migraine are among those in the tar get population for lasmiditan.  Therefor e, it is important to 
assess further safety due to the BP response observed in Study LAHA .  The current study will testwhether each 
dose level of lasmiditan (100 and 200 mg) is noninferior to placebo with re gard to increasing SBP.  The intended 
sample size will have at least 90% power to detect a true mean increase of 5mmHg in SBP change from baseline
between lasmiditan and placebo , assuming a 1-sided significance level of 0.05 and a noninferiority margin of 
10mmHg .
Objective(s)/Endpoints:
Objectives Endpoints
Primary
To testwhether each oral dose of lasmiditan ( 100 and 
200 mg) is noninferior to placebo with regard to 
increasing blood pressure in healthy  elderly  subjects 
(≥65 y ears of age ).Systolic blood pressure  obtained via 
ambulatory blood pressure monitoring (ABPM)
Secondary
To determine the PK of lasmiditan in healthy elderly 
subjects ( ≥65 years of age) f ollowing single 100- and 
200-mg oral dose sof lasmiditan .
To assess the safety and tolerability of 100- and200-
mg o ral dose sof lasmiditan in healthy  elderly  subjects.PK parameters:  maximum observed drug 
concentration (Cmax), time of Cmax (tmax), 
and the area under the concentration versus time 
curve from zero to infinity (AUC[0 ∞])
A sum mary  of the number of treatment -
emergent adverse events (TEAEs) and serious 
adverse events (SAEs)
Summary of Study Design :
This is a randomized, subject -and investigator -blind ,placebo -controlled crossover study with 3 treatment periods to 
assess BP , PK, and safety and tolerability of 100- and200-mg oral dose sof lasmiditan in healthy elderly subjects.  
All s ubjects will participate in 3 treatment periods.  The treatments are as follows:
H8H-MC-LAIG Clinical Pharmacology Protocol Page 8
LY573144Treatment A: Lasmiditan 200 mg
Treatment B: Lasmiditan 100 mg
Treatment C:   Placebo
Each subject will be randomized to 1of 6treatment sequences in a Williams design (i.e. ABC, BCA, CAB, CBA, 
ACB, BAC). 
Treatment Arms and Planned Duration for an Individual Subject :  
Screening Period:
All subjects will participate in a screening visit up to 28days prio r to study  drug dosing.  
Dosing Period:
All s ubjects will participate in 3 treatment periods.  Subjects will be randomized to 1 of 6 treatment sequences .  
They  will be admitted to the clinical research unit ( CRU )the day prior to dosing (Day -1), and receive study drug on 
Days 1, 3, and 5 .  Subjects willbe discharged from the CRU on Day 7 .  There will be a washout period of
approximately 48 hours between each dosing day.  Subjects willremain confined during the entire inpatient period. 
Number of Subjects :
Up to 3 6subjects may be enrolled to ensure 30subjects complete the study.  S ubjects will be aged ≥65 years.  
Attempts will be made to enroll at least 6subjects who are aged ≥75 y ears.
Statistical Analysis:
Cardiovascular parameters that will be assessed using ABPM include peak hourly mean values of SBP .The 
parameters will be listed, and summarized using descriptive statistics, as appropriate.   Changes from baseline in 
peak hourly mean values of SBP will be analy zed to test whether each dose of lasmiditan (100 and200 mg) is 
noninferio r to placebo, assuming a noninferiority margin of 10 mmHg.  A linear mixed -effects model with baseline 
as a covariate, fixed effects for treatment, period (1, 2, or 3), and trea tment sequence, and a random effect for subject 
will be used to test thehypotheses at a 1-sided significance level of 0.05. Agatekeeping procedure will be used to 
adjust for multiplicity when conducting thehypothesis tests comparing lasmiditan 100 mg with placebo and 
lasmiditan 200 mg with placebo.
Safety parameters that will be assessed include safety laborator y parameters ,vital signs ,DBP ,andpulse rate 
obtained via ABPM, and adverse events .  The parameters will be listed, and summarized using standard descriptive 
statistics, as appropriate.   
Pharmacokinetic parameter estimates for lasmiditan will be calculated using standard noncompartmental methods of 
analy sis.  The parameters will be listed, and summarized using standard descriptive statisti cs, including estimates of 
intra-subject variability as appropriate.   
H8H-MC-LAIG Clinical Pharmacology Protocol Page 9
LY5731442.Schedule of A ctivities
H8H-MC-LAIG Clinical Pharmacology Protocol Page 10
LY573144Study Schedule Protoco l H8H -MC-LAIG
ScreeningInpatient PeriodDischarge 
from 
Clinic or 
Early 
Term 
ProceduresFollow up Comments
Procedure-28 to -2 
days prior 
to Day 1Day -1 Day 1Day 
2Day 3Day 
4Day 5Day 
6Day 7Day 10 ± 2 
days
Informed Consent X
C-SSRS and Self 
Harm Supplement
FormX X X XFor the C -SSRS, use Baseline 
Version at screening and Since 
Last Visit V ersion at all other 
visits .
Subject Admission 
to CRUX
Subject Discharge 
from CRUX
RandomizationXRandomization to occur prior to 
dosing.
Investigational 
Product 
AdministrationX X X
Medical History
X XAfter screening, medical history 
should include interim medical 
history .
AEs and 
Medication reviewX X X X X X X X X X
Height X
Weight X
Temperature X
Vital Signs
(supine) X XPre-
dose
and4 h24 hPre-
dose 
and 4 h24 
hPre-
dose
and4 h24 h XaXVital signs will be single
measure s.
The pre -dose measure is taken 
H8H-MC-LAIG Clinical Pharmacology Protocol Page 11
LY573144before the ABPM recordings 
are started .
Time points may be added if 
warranted and agreed upon 
between Lilly and the 
investigator .
H8H-MC-LAIG Clinical Pharmacology Protocol Page 12
LY573144ScreeningDosing PeriodDischarge 
from Clinic 
or Early 
Term 
ProceduresFollow up Comments
Procedure-28 to -2 
days prior 
to Day 1Day -1 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7Day 10 ± 2 
days
Orthostatic Vital 
Signs X
Ambulatory Blood 
Pressure 
MonitoringX X XThe ABPM device 
will be worn for 
approximately 
2hours before dosing 
and will continue to 
be worn until the 24 -
hour postdose 
assessment is 
complete.   See 
Section 9.4.2.1 for 
details.
ABPM Training XSubjects should be
trained on the ABPM 
device on the evening 
of Day -1.  Data from 
this acclimation 
period will not be 
stored or analyzed.
Clinical Lab oratory
Tests X X XSee Appendix 2 , 
Clinical Laboratory 
Tests, for details.
Ethanol Test
XSee Appendix 2 , 
Clinical Laboratory 
Tests, for details.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 13
LY573144Urine Drug Screen 
X XSee Appendix 2 , 
Clinical Laboratory 
Tests, for details.
Physical 
Exam ination
X X X X X X XFull physical 
examination at
screening .  Symptom -
driven phy sical 
examination for all 
other time points.
12-lead ECG
XPre-
dose
and4 h24 hPre-
dose
and 4 h24 hPre-
dose
and4 h24 hSingle ECG readings 
will be taken. The 
pre-dose measure is 
taken before the 
ABPM recordings are 
started .
PK Samples Pre-
dose, 
0.5, 1, 
1.5, 2, 
2.5, 3, 
4, 6, 8, 
1224, 36Pre-
doseb, 
0.5, 1, 
1.5, 2, 
2.5, 3, 
4, 6, 8, 
1224, 36Pre-
doseb, 
0.5, 1, 
1.5, 2, 
2.5, 3, 
4, 6, 8, 
1224, 36 48c
Genetic Sample
XSingle sample for 
pharmacogenetic 
analy sis taken prio r 
to/on Day  1.
Abbreviations:  ABPM = ambulatory blood pressure monitoring; AE = adverse event; CRU = clinical research unit; C-SSRS = columbia -suicide severity rating 
scale ; ECG = electrocardiogram; min = minutes; PK = pharmacokinetics. 
aThe Day 7 vital sign measurement should be ta ken approximately 48 hours after the previously administered dose
bPre-dose should be collected approximately 48 hours after the previously administered dose.
cUnscheduled PK samples should be drawn for subjects following early termination procedures.
Note:  if multiple procedures take place at the same time point, the following order of the procedure should be used:  ECG, sup ine vital signs, and orthostatic vital 
signs, venipuncture.  Where venipuncture and other procedures take place at the same time po int, the following time windows for obtaining blood samples 
should be maintained:  >0 to 2 hours postdose: ±5 minutes; 2.5 to 6 hours postdose: ±10 minutes; 7 to 12 hours postdose: ±20 minutes; >12 hours postdose: 
±30 minutes.  Where repeats of vital signs measurements are required, repeats should be performed after venipuncture.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 14
LY5731443.Introduction
3.1. Study Rationale
Lasmiditan is a small mo lecule 5-hydroxy tryptamine ( 5-HT1 F)receptor agonist being developed 
for the acute treatment of migraine.  Triptans, which are 5 -HT1 B/1Dreceptor agonists, are well 
established as an acute therapy  for migraine, though they  are not effect ive in all pat ients or 
attacks. Triptans were develop
ed as cerebral vasoconstrictors, mediated via their affinit y for 
5-HT1 Breceptors located on vascular smooth muscle. Inherent in this mechanism o f action is a 
liabilit y for coronary  vasoconstri ction, and therefore, triptans are contraindicated in pat ientswith 
cardi ovascular di sease. Unlike triptans, lasmiditan is a highly  select ive and potent agonist at the 
5-HT1 Freceptor with >470
-fold higher affinit y for the 5 -HT1 Freceptor than for 5- HT1 B/1D
receptors. Lasmiditan is under development as a neurally a cting treatm ent for migraine wi thout 
the vasoconstrictor liabilit y of tri ptans .
The prevalence of migraine declines in the popul ation older than 50 y ears of age ;however ,
5%
to 10% of the populat ion older than 65 years of age still report suffering from migraine (Victor 
etal. 2010).  Thus, e lderly patients are anticipated to receive lasmiditan.
Study  H8H -MC-LAHA (LAHA) was recent ly conducted to determine the pharmacokinet ics 
(PK)and safet y of lasmidi tan in elderly and y oung heal thy subjects fo llowing a si ngle oral  
administration of lasmiditan 200 mg. The study  database has been locked but the clinical study  
report has not been finalized. A review of preliminary data from the elderly cohort showed that 
following administration of lasmiditan 200 mg, there was a transient elevat ion in mean supine 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) between 60 and 90 minutes 
postdose, with a mean maximum increase in SBP of 14.5 mmHg and in DBP of 3.8 mmHg 
compared to baseline.  Since the number of subjects enro lled in LAHA was based on statist ical 
power to detect differences in PK, it was not possible to determine if the observed effects on 
blood pressure ( BP)were statist ically significant. Therefore, it is important to assess furth er 
safet y due to the response of BP observed in Study LAHA.  The current study  will test whether 
each dose level of lasmid itan (100 and 200 m g) is non inferi or to pl acebo wi th regard to 
increasing SBP.  The intended sample size will have at least 90% power to detect a true mean 
increase of 5mmHg in change in SBP from baseline between lasmiditan and placebo, assuming 
a 1-sided significance level o f 0.05 and a noninferiority  margin o f 10 mmHg.
3.2. Background
Across the completed Phase 1, 2, and 3 clinical studies , doses of 0.1 to 400 mg of lasmiditan 
were evaluated in healt hy subjects or patients with migraine. Com pared wi th placebo, the m ost 
frequently reported lasmiditan treatment -emergent adverse events (TEAEs) included dizziness, 
paresthesia, somno lence, fati gue, l ethargy , and nausea . Amajorit y of these TEAEs were mild or 
moderate in severit y and none led to subject withdrawal. One patient experienced a serious 
adverse event (SAE) of dizziness that was moderate in severit y (lasmidi tan 200 m g) (Färkkilä 
etal. 2012) .
H8H-MC-LAIG Clinical Pharmacology Protocol Page 15
LY573144In the thorough QT study  in healt hy subjects, no clinically significant changes in BP, heart rate, 
or 12 -lead electrocardi ogram  (ECG )were observed at the 100 -or 400 -mg single -dose l evels.
In healthy subjects, peak plasma concentrations of lasm iditan were observed approximately 
1.5to 2.5 hours after a single oral dose ranging from 25 to 400 mg, and the geometric mean 
terminal half -life was approximately  4 hours. Lasmiditan exhibited dose -linear PK. 
Co-administration of lasmiditan with a high -fat di et led to a del ay in median t ime of maximum 
observed drug concentration (tmax) value by approximately 1 hour and a modest (~20%) 
increase in lasmiditan maximum observed drug concentration (Cmax),and area under the 
concentration versus t ime curve (AUC
)values, relative to that under fasted condit ions.
Following oral  dosing wi th lasmidi tan, up to 11 metabolites were detected in human plasma and 
urine, including 3 major metabo lites (M7, M8, and M18).  These metabo lites lacked significant 
pharmaco logical activity at the 5 HT1 Freceptor and were generally considered to be 
pharmaco logically inact ive.  The relat ive proportions o f metabolites to intact l asmidi tan 
remained reasonably constant throughout the oral dose range studied and their PK w as
approximate ly linear.  The half -life of the metabo lites ranged fro m ~4.5 to 21hours.
Preliminary PK results fro m Study LAHA demonstrated that i n elderly subjects, exposure to 
lasmiditan as measured by  AUC fro m zero to infinit y was 26% (90% confidence intervals ( CIs)
1.03, 1.55) higher than in young subjects fo llowing dosing wi th 200 m g lasmidi tan.  There was 
no stati stically significant difference in exposure to lasmiditan based on Cmax.  The tmax of 
lasmiditan was similar between age groups.   The geometric mean t 1/2was 5.46 and 4.10 hours in 
elderly  and y oung subjects, respectively.
Preliminary safet y data from  Study  LAHA show that s ingle doses of 200 mg lasmiditan were 
well tolerated by 18healthy elderly and 17 healt hy young subjects in this study , with noreporte d
deaths ,other SAEs, or discont inuat ions due to adverse events ( AEs).  The types of TEAEs 
reported were consistent with previous studies of lasmiditan in healthy subjects.  In elderly 
subjects, postdose there was a transient elevat ion in mean supine systo lic blood pressure (SBP) 
and diastolic blood pressure (DBP) between 60 and 90 minutes postdose, with a mean maximum 
SBP increase of 14.5 mmHg and DBP increase of 3.8 mmHg compared with baseline  . The 
changes in supine vital signs were maximal at approxima tely 1.5 hours postdose and had 
returned toward baseline values by the t ime of the assessment at 3 hours postdose.  No such 
changes were noted in elderly subjects receiving placebo or in young subjects receiving 
lasmiditan.  There were no apparent postdose trends in orthostatic vital signs for any  age group.
3.3. Benefit/Risk Assessment
The primary  object ive ofthis study  is to eval uate the cardio vascular effects after single oral100-
and 200 -mgdoses of lasmidi tanin healt hy elderly subjects .  There is no anticipated therapeutic 
benefit for the subjects.
Lasmiditan has been generally well tolerated by  heal thy subjects as single oral  doses up to 
400 mg.  Elderly patients were enrolled in the completed Phase 3 program, for acute treatment of 
migraine, that tested single oral doses up to 200 mg, where a second dose was permitted within 
H8H-MC-LAIG Clinical Pharmacology Protocol Page 16
LY573144the sam e day  if migraine relief had not been achieved.  In addit ion, Study  LAHA tested 200 m g 
lasmiditan in 18 elderly subjects .
In com pleted clinical studi es wi th single l asmidi tan oral  doses up to 400 m g, the m ost frequent ly 
reported lasmiditan TEAEs included tiredness, drowsiness, dizziness, and paresthesia . A
majorit y of these TEAEs were mild in severit y and none l ed to subject withdrawal. One patient 
experienced a nSAE of dizziness that was moderate in severit y (lasmidi tan 200 m g).  Dosing of 
lasmiditan in this study  will be conducted in an inpatient setting, and subjects will be monitored 
in the clinical research unit ( CRU )for at least 48 hours after each dosing.
More informat ion about the known and expected benefits, risks, SAEs ,and reasonably 
anticipated AEs of lasmiditan isto be found in the Invest igator’s Brochure ( IB).
H8H-MC-LAIG Clinical Pharmacology Protocol Page 17
LY5731444.Objectives and Endpoints
Table LAIG 1shows the object ives and endpo ints of the study .
Table LA IG 1. Objectives and Endpoints
Objectives Endpoints
Primary
To test whether each oral dose of lasmiditan (100 and 
200 mg) is non inferior to placebo with re gard to 
increasing blood pressure in healthy elderly  subjects 
(≥65 y ears of age ).Systolic blood pressure obtained via ambulatory 
blood pressure monitoring (ABPM)
Secondary
To determine the PK of lasmiditan in healthy elderly 
subjects ( ≥65 years of age) following single 100- and 
200-mg oral dose sof lasmiditan.
To assess the safety and tolerability of 100 -and 200-mg 
oral dose sof lasmiditan in healthy elderly subjects.PK parameters:  maximum observed drug 
concentration (Cmax), time of Cmax (tmax), and 
the area under the concentration versus time 
curve from zero to infinity (AUC[0 -∞])
A sum mary  of the number of treatment -
emergent 
adverse events (TEAEs) and serious advers e 
events (SAEs)
H8H-MC-LAIG Clinical Pharmacology Protocol Page 18
LY5731445.Study  Design
5.1. OverallDesign
This is a rando mized, subject -and invest igator -blind ,crossover study  with 3 treatm ent peri ods in 
healt hy elderly subjects.  The treatments are as fo llows:
Treatment A: Lasmiditan 200 mg
Treatment B: Lasmiditan 100 mg
Treatment C: Placebo
Each subject will be rando mized to 1 of 6 treatm ent sequences in a Williams design ,as outlined 
in Table 5.1.
Study  governance considerations are described in detail in Appendix 3 .
Table 5.
1. Sequences in Study LAIG
Sequence Period 1 Period 2 Period 3
1 Lasmiditan 200 mg Lasmiditan 100 mg Placebo
2 Lasmiditan 100 mg Placebo Lasmiditan 200 mg
3 Placebo Lasmiditan 200 mg Lasmiditan 100 mg
4 Placebo Lasmiditan 100 mg Lasmiditan 200 mg
5 Lasmiditan 200 mg Placebo Lasmiditan 100 mg
6 Lasmiditan 100 mg Lasmiditan 200 mg Placebo
Screening Period: 
All subjects will part icipate in a screening visit up to 28 days prior to study drug dosing.
Dosing Period:
Subjects will part icipate in 1inpatient period invo lving 3dosing periods.  Subjects will be 
admitted on Day  -1 and will be rando mized to 1 of 6 treatm ent sequences to receive lasmiditan 
or placebo on Day s 1, 3 ,and 5 .  There will be a wash out peri od of  approximately  48 hours 
between each dosing day.  Subjects may be discharged on Day 7 based on invest igator s’
discreti on.
All subjects will be discharged from the study  approximately  2days aftertheir final  dose of 
lasmiditan.
5.2. Number of Participants
Up to 36 subjects may be enro lled to ensure 30subjects complete the study .  Subjects will be 
aged ≥65 y ears.  Attempts will be made to enroll at least 6subjects who are aged ≥75 y ears.  
H8H-MC-LAIG Clinical Pharmacology Protocol Page 19
LY573144Subjects who discont inue from the study  prior to com pletion m ay be repl aced at the discret ion of 
the sponsor .
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) for the last subject .
5.4. Scientific Rationale for Study Design
A rando mized, subject -and investigator -blind, placebo -controlled design is being used to 
minimize bias on the safet y and tol erabilit y object ive.  A crossover design improves the 
sensit ivity for detecting any  safety /tolerabili ty signals in el derly subjects, particularly in relat ion 
to vital signs (as described in Section5.1).
The was hout period of approximately 48 h between each dose is adequate based on the half -life 
of lasmidi tan.
The nonclinical and clinical data enable conduct ing clinical pharmaco logy studi es in el derly 
healt hy subjects.  The single -dose desi gn of  this study  limits exposure of subjects to lasmiditan 
and is appropriate to address the study  object ives.
5.5. Justification for Dose
The upper dose l evel of 200 mg lasmidi tan has been well  tolerated in previous studies of healt hy 
subjects and in elderly pat ients enro lled in the compl eted Phase 3 program .  Thi s dose l evel is in 
the therapeutic dose range and is expected to be the highest potential recommended single dose 
for lasmidi tan. A lower dose of 100 mg lasmiditan will a lso be evaluated in the current study  to 
explore any cardi ovascular effect.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 20
LY5731446.Study  Population
Eligibilit y of subjects for the study  will be based on the results of screening medical history , 
physical examinat ion, vital signs , clinical laboratory tests, and ECG .
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening may occur up to 28 day s prior to Day 1.  Subj ects who are not enrolled within 28 days
of screening m ay be subjected to an addit ional medi cal assessment and/or clinical measurements 
to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment c riteria, al so known as 
protocol  waivers or exempt ions, is not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria at 
screening and enrollment (Day 1):
[1] are overtly healt hy males or females, as determined through medical history  and 
physical examinat ion  
[1a] male subjects:
are not required to adhere to con tracepti ve requi rements.
[1b] female subjects:
of non-childbearing potential ,i.e. postm enopausal  or p ermanent ly sterile 
following hysterectomy, bilateral salpingectomy or confirmed tubal occlusion 
(not tubal ligat ion), as determined through medical history .  Postm enopausal  is 
defined as spontaneous amenorrhea for at least 12 months, and a plasma 
follicle -stimulat ing hormone level greater than 40 mIU/mL, unless the subject 
is taking hormone replacement therapy .
[2] are aged ≥65years.
[3] have a body  mass index ( BMI )of 19.0to 35 .0kg/m2, inclusive, at the time of 
screening.
[4] have clinical laboratory  test resul ts wi thin norm al reference range for the population 
or investigator site, or results with acceptable deviations that are judged to be not 
clinically significant by  the investi gator.
[5] have venous access sufficient to allow for blood sampling as p er the protocol.
[6] are reliable and willing to make themselves available for the duration of the study  
and are willing to follow study  procedures.
[
7]have given written informed consent approved by Lilly and the ethical review boa rd 
(ERB) governing the site.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 21
LY5731446.2. Exclusion Criteria
Subjects will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment (Day 1):
[8] are invest igator site personnel direct ly affiliated with this study and their immediate 
families .  Immediate family is defined as a spouse, parent, child or sibling, whether 
biological  or legally  adopted.
[9] are Lilly  or Covance empl oyees.
[10] are currently enrolled in a clinical  study  involving an invest igational product or any  
other ty pe of medic al research judged not to be scient ifically or medically 
compatible with this study.
[11] have known allergies to lasmidi tan, rel ated com pounds ,or any  com ponents of the 
formulation.
[12]are persons who have previously received lasmidit an.
[13]have a history  of, or ECG findings of, clinically significant brady cardia, heart block, 
tachy  or brady  arrhy thmias, or have any other abnormalit y in the 12 -lead ECG that, 
in the opinio n of the invest igator, increases the risks associated with participat ing in 
thestudy .
[14]have significant history  of or current cardi ovascular, respi ratory ,hepatic, renal, 
gastrointestinal, endocrine, hematological, or neurological disorders capable of 
significant ly altering the absorpti on, m etabo lism, or eliminat ion of drugs; o f
constituting a risk when taking the study  medicati on; or of interfering with the 
interpretati on of  data.   Appendectomy, splenectomy, and cho lecystectomy are 
considered as acceptable.
[15]show evidence of significant active neuropsy chiatric disease ( e.g.manic depressive 
illness, schizophrenia, depressio n)considered as clinically  significant by  the 
investigator .
[16]show a history  of central  nervous sy stem  (CNS) condit ions such as strokes, transient 
ischemic attacks, significant head trauma, seizures, CN S infect ions, migraines, brain 
surgery ,or any  other neurol ogical condi tions that, in the opinio n of the invest igator , 
increase the risk of participat ing in the study .
[17]
show evidence of active renal disease ( e.g.diabet ic renal disease, polycyst ic kidn ey 
disease) or estimated glomerular filtration rate <60mL/min /1.73 m2.
[18]currently use, or within the past 1 y ear used recreatio nal drug use, or showed 
evidence of substance dependence within the past 6 months based on history  at 
screening visit .
[19] show evidence of human immunodeficiency  virus (HIV) infecti on and/or posi tive 
human HIV ant ibodies /antigens .
[20]show evidence of hepatit is C and/or positive hepat itis C ant ibody .
H8H-MC-LAIG Clinical Pharmacology Protocol Page 22
LY573144[21]show evidence of hepatit is B and/or positive hepat itis B surface antig en.
[22]intend to use over -the-counter or prescript ion medication, dietary  supplements ,or 
strong inhibitors or inducers of cytochrom e P450 (CYP )1A and CYP3A activit ies 
within 14 days pri or to dosing of l asmidi tan.  
Excepti ons all owable for subjects on a 
stable dose of hormone replacement therapy , thyroid repl acement therapy , 
prophylact ic anti -platel et drugs, angi otensin -converti ngenzyme (ACE) inhibitors, 
angiotensin receptor blockers (ARBs), thiazides, statins, or protein pump inhibitors 
(PPIs) for at le ast 3 m onths prior to admissio n; medications falling into the 
exceptions listed above, and/or others that may be considered not to impact study  
integrity may be all owed f ollowing discussio n with the Lilly clinical research 
physician ( CRP )/CP or desi gnee.
[23] have donated blood of more than 500 mL within 2months prior to the screening 
visit.
[24]have an average weekly  alcohol  intake that exceeds 14 units per week or are 
unwilling to stop alcoho l consumption 48 hours prior to admissio n unt il the 
completionof the study  (1 uni t = 12 oz or 360 m L of beer; 5 oz or 150 mL of wine; 
1.5 oz or 45 mL of distilled spirits).
[25]have a history  of syncope, presyncopy , uncontrolled vertigo, postural dizziness, or at 
risk for falls , as judged to be clinically significa nt by the investigator.
[
26]are unwilling to refrain fro m tobacco -or nicotine -containing products while in the 
CRU or are unable to abide by CRU restrictions.
[27]have orthostati c hypotensio n with or wi thout di zziness and/or syncope at screening
(or upo n repeat) or a history  of it.
[28] have a history  of, show evi dence of, or are undergoing treatment for significant 
active neuropsy chiatri c disease ( e.g.manic depressive illness, schizophrenia, 
depressio n), have a recent history  of a sui cide attempt (30 day s within screening 
visit and any t ime between screening visit and baseline); or are clinically judged by 
the invest igator to be at risk for suicide.
[29] in the opinio n of the invest igator or sponsor, are unsuitable for inclusion in the 
study .
6.2.1. Rationale for Exclusion of Certain Study Candidates
The use of lasmiditan in elderly pat ients is ant icipated, thus this study  will specifically examine 
the PK, safet y, and tol erabili ty in an elderly popul ation.  Cri terion2 define sthe elderly  
popul ation for the purposes of this study .
6.3. Lifestyle and/or Diet ary Requirements
Throughout the study ,subjects may undergo medical assessment sand review of compliance with 
requirements before continuing in the study .
H8H-MC-LAIG Clinical Pharmacology Protocol Page 23
LY5731446.3.1. Meals and Dietary Restrictions
Lasmiditan or placebo will be administered after an overnight fast of at least 8 hours.  Subjects 
will be given a snack prior to bedtime.  Subjects will abstain from water 1 hour before and after 
dosing (except for water given with the dose).  Subjects may be permitted to consume a light 
breakfast (e.g. cereal, toast) at 1 h our postdose at the discret ion of the investigator; with the 
exception of this light breakfast, subjects will remain fasting for 3 hours postdose at which time a 
meal will be served.
6.3.2. Caffeine, Alcohol, Tobacco , and Grapefruit
Caffeine –Subjects will refra in from consuming xanthine -or caffeine -containing food and 
drinks fro m 48hours prior to admissio n, and while resident at the CRU.
Alcohol –Subjects will not consume alcoho l for 48 hours prior to admissio n, and while resident 
at the CRU.
Tobacco –Subjects will refrain fro m using tobacco -or nicotine -containing products while 
resident at the CRU.
Grapef ruit–Subjects will refrain fro m consuming grapefruit and grapefruit -containing products 
from 7 days pri or to Day  1, and while resident at the CRU .
6.3.3. Activity
No strenuous exercise will be allowed for 48 hours prior to admissio n unt il after follow-up visit.
6.4. Screen Failures
Individuals may  be re-screened once .  The interval between re-screenings should be at least 
1week.  When re -screening is performed, the individual must si gn a new informed consent form 
(ICF) andwill be assigned a new ident ificat ion number.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 24
LY5731447.Treatment
7.1. Treatment Administ ered
Invest igational products used in this study  are shown in Table 7.1.
Tablets of lasmiditan and/or placebo will be administered orally in the fasted state with 
approximately  240 mL of room  temperature water in the morning of Day s 1
, 3, and 5 ,while 
subjects ar e in a sitting posit ion.  Subjects will not be allowed to lie supine for 2 hours after 
dosing, unless clinically  indicated or for study  procedures.
Table 7.1
. Treatment sAdministered
Treatment Name Lasmiditan Placebo
Dosage Formulation Film-coated tablet Film-coated tablet 
(matching to lasmiditan )
Unit Dose Strength 100-mg tablet --
Route of Administration Oral Oral
Dosing Instructionsa1 or 2 x tablet taken in the morning of 
each dosing day1 or 2 x tablet taken in the morning of 
each dosing day
aAll subjects willreceive 2 tablets at each dosing occasion , i.e. 1 x 100-mg tablet plus 1 matching placebo tablet, 
or 2 x 100 mg tablet, or 2 matching placebo tablets .
The invest igator or designee is responsible for
explaining the correct use of the investigational product (s) to the site personnel
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection
and returning all unused medication to Lilly or its designee at the end of the study
Note : In some cases, sites may destroy  the m aterial  if, during the invest igativesite select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical materials .
7.1.1. Packaging and Labeling
Each tablet of lasmiditan contains 100mg of act ive ingredient and is provided as bulk supply in 
bottles.  Placebo tablets look ident ical but contain no active ingredient and will be provided in 
similar bulk bottles.
The invest igational product will be labeled according to the country’s regula tory requi rements.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 25
LY5731447.2. Method of Treatment Assignment
All subjects will part icipate in 3 treatment periods.  The treatments are as fo llows:
Treatment A: Lasmiditan 200 mg
Treatment B: Lasmiditan 100 mg
Treatment C: Placebo
Each subject will be rando mized to on e of 6 treatment sequences in a Williams design (i.e. ABC, 
BCA, CAB, CBA, ACB, BAC) using a co mputer -generated allocat ion schedule.
7.2.1. Selection and Timing of Doses
Subjects will receive study  drugs o n Day s 1,3, and 5 .
The actual  time of all dose administrations will be recorded in the subject’s case report form 
(CRF).
7.3. Blinding
This study  will be subject -and invest igator -blind.  The invest igator, site staff (except unblinded 
pharmacy staff), and subjects will be blinded to study  treatm ent.
Emergency  codes will be available to the invest igator.  A code, which reveals the treatment for a 
specific study  subject, m ay be opened during the study  only if th e subject’s well -being requires 
knowl edge of the subject’s treatment ass ignment.
If a subject’s study  treatm ent assignment is unblinded, the subject must be discont inued from the 
study , unless the invest igator obtains specific approval fro m a Lilly clinical pharmaco logist (CP) 
or CRP for the study  parti cipant to continue in th e study .  During the study , emergency 
unblinding should occur only by accessing the study subject’s emergency code.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a subject’s treatm ent assi gnment i s warranted for m edical management of the event.  The 
subject’s safet y must always be the first consideratio n in making such a determinat ion.  If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
prom ptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
Upon com pletion of the study , all codes must be returned to Lilly or its designee.
7.4. Dose Modification
Dose m odificat ion will not be allowed during the study .
7.5. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm all investigat ional product was received in good 
condi tion, and any  discrepancies are reported and resolved before use of the study  treatm ent.
Only participants enro lled in the study  may receive invest igational product or study  materials, 
and only  authori zed si te staff may  supply  or administer invest igational product.  All 
H8H-MC-LAIG Clinical Pharmacology Protocol Page 26
LY573144investigat ional product should be stored in an environmentally  controlled and mo nitored (m anual  
or automated) area in accordance wit h the l abeled storage condit ions wit h access limited to the 
investigator and authorized site staff.
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
respon sible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance (such as 
recei pt, reconciliat ion,and final disposit ion records).
7.6. Treatment Compliance
The invest igational product will be administered at the clinical site, and documentation of 
treatm ent administration will occur at the site.
7.7. Concomitant Therapy
Concomitant medicat ions are to be avoided during the study  unless required to treat an AE or for 
the treatment of an ongo ing medical problem.
Acetaminophen may be allowed at the inves tigator’s discret ion, up to 2 g in a 24- hour peri od, 
without pri or consul tationwith the sponsor .
Stable dose sof horm one repl acement therapy , thyroid repl acement therapy , prophylact ic 
antiplatelet drugs, ACE inhibitors, ARBs, thiazides, statins, or PPIs f or at l east 3 m onths prior to 
admissio n. M edications falling into the except ions listed above, and/or others that may be 
considered not to impact study  integrity may be allowed following discussio n with the Lilly  
CRP/CP or designee.
If the need for concom itant m edicat ion (other than acetaminophen) arises, inclusio n or 
continuat ion of the subject may be at the discret ion of the invest igator after consultation wit h a 
Lilly CP, CRP, or desi gnee.  Any  medicat ion used during the course of the study  must be 
docu mented.
7.8. Treatment after the End of the Study
This sect ion is not applicable to this study .
H8H-MC-LAIG Clinical Pharmacology Protocol Page 27
LY5731448.Discontinuation Criteria
Subjects discont inuing fro m the study prematurely for any  reason must com plete adverse event 
(AE) and discharge procedures per Section 2of this protocol .
8.1. Discontinuation from Study Treatment
Discontinuati on of  the invest igational product for abnormal liver tests should be considered by 
the invest igator when a subject meets 1 of the fo llowing condit ions after consultation with the 
Lilly -designated m edical m onitor:
alanine aminotransferase (ALT), aspartate aminotransferase (AST) >5X upper limit of 
norm al (ULN)
ALT or AST >3X ULN and total bilirubin >2X ULN or internat ional norm alized rati o 
(INR) >1.5
ALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, right upper-
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
alkaline phosphatase (ALP) >3X ULN
ALP >2.5X ULN and total bilirubin >2X ULN
ALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%) .
8.1.1. Discontinuation of Inadvertently Enrolled Subjects
If the sponsor or invest igator ident ifies a subject who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  CP/CRP or desi gnee and the 
investigator to determine if the pat ient may cont inue in the study .  If both agree i t is medically  
appropria te to conti nue, the invest igator must obtain documented approval fro m the Lilly 
CP/CRP or desi gnee to allow the inadvertent ly enrolled patient to con tinue in the study  with or 
without continued treatment with invest igational product.
8.2. Discontinuation from the Study
Subjects will be discont inued under the following ci rcumstances:
Enrollment in any other clinical study  involving an invest igational product or enrollment 
in any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator decides that the subje ct shoul d be discontinued from the study
H8H-MC-LAIG Clinical Pharmacology Protocol Page 28
LY573144Subject Decisio n
othe subject, or legal representative, requests to be withdrawn from the study .
8.3. Subjects Lost to Follow -up
A subject will be considered lost to follow -up if he or she fails to return for a scheduled visit and 
is unable to be contacted by  the study  site.  Si te personnel are expected to make diligent attempts 
to con tact subjects who fail to return for a scheduled visit or were otherwise unable to be 
followed up by  the si te.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 29
LY5731449.Study Assessments and Procedu res
Secti on 2 lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the laboratory tests that wi ll be perform ed for this study .
Appendix 5 provi des a summary of the maximum  number and vo lume of invasive samples, for
all sampling, during the study .
Unless otherwise stated in subsect ions below, all samples collected for specified laboratory  tests
will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
This section is not applicable for this study.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of subjects who have entered this study 
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
consi dered an unant icipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible fo r following, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the subject to discontinue the invest igational product before 
completing the study.  The subject should be fo llowed unt il the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow
-up 
evaluat ions of the AE is left to the discret ion of the invest igator.
After the ICF i s signed, study  site personnel will record, via electroni c case report form (eCRF), 
the occurrence and nature of each subject’s preexisting condit ions, including clinically  
significant si gns and symptom s of the disease under treatment in the study .  Addi tionally , site 
personnel will record any  change in the condi tion(s) and the occurrence and nature of any  AEs.
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent or a s tudy procedure, taking into account the concomitant 
treatm ent or pathologies.
A “reasonable possibilit y” means that there is a potential cause and effect relat ionship between 
the invest igational product and/or study  procedure and the AE.
Planned surgeries shoul d not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
H8H-MC-LAIG Clinical Pharmacology Protocol Page 30
LY573144If a subject ’sinvest igational product is discont inued as a result of an AE, study  site personnel  
must report thi s to Lilly  or its designee v ia eCRF.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1 of the f ollowing:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience ( i.e. immediate risk of dying)
persistent or significant disabilit y/incapacity
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but m ay jeopardi zethe pati ent or may  requi re intervent ion to prevent 1 
of the other outcomes listed in the d efinit ion above.
Study  site personnel  must al ert the Lilly  CRP/CP, or i ts desi gnee, of  any SAE as soon as 
pract ically possible.
Addit ionally , study site personnel  must al ert Lilly Global Patient Safet y,or its desi gnee ,of any 
SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved method.  If 
alerts are issued via telephone, they  are to be immedi ately fo llowed wi th official notification on 
study -specific SAE forms.  This 24 -hour notificat ion re quirement refers to the init ial SAE 
inform ation and all fo llow-up SAE information.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued from and/or com pleted the study  (the subject summary CRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly . 
Pregnancy (maternal or paternal exposure to investigat ional product ) does not meet the definit ion 
of an AE.  However, to fulfill regulatory  requi rements any pregnancy  should be reported 
following the SAE process to colle ct data on the outcome for both mother and fetus.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to inves tigational product or procedure .  Lilly  
has procedures that will be fo llowed for the recording and expedited reporting of SUSARs that 
are consistent with global regulations and the associated detailed guidances.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 31
LY5731449.2.2. Complaint Handling
Lilly co llects product co mplaints on invest igational products and drug delivery systems used in 
clinical trials in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to facilitate 
process and product improvements.
Subjects shoul d be instructed to contact the in vestigator as soon as possible if he or she has a 
complaint or probl em wi th lasmidi tan so that the situation can be assessed.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of lasmiditan is considered any dose higher than the 
dose assigned through rando mizat ion.There is no specific ant idote for lasmiditan. In the event 
of overdose, the subject should receive appropriate supportive care and AEs should be 
docum ented. 
Refer to the IB.
9.4. Safety
9.4.1. Laboratory Tests
For each subject , laboratory  testsdetailed in Append ix 2shoul d be conducted accordi ng to the 
Schedule of Activities (Secti on2).
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the subject receives the first dose of invest igational product should be reported to Lilly  or 
its designee as an AE via eCRF.
9.4.2. Vital Signs
For each subject , vital sign measurements should be conducted according to the Schedule o f 
Activities (Secti on 2) .
Blood pressure and pulse rate ( PR)should be measured singly after at least 5 minutes supine.
For each individual subject, the same cuff size should be used throughout the study  for the 
measurements of BP. The cuff should be attached to the subject’s dominant arm (nondo minant 
arm will be used for ambulatory  blood pressure moni toring [ABPM
])
.
Where orthostatic measurements are required, subjects should be supine for at least 5 minutes 
and then subjects will stand, and standing BPwill be measu red after 2 minutes; no longer than 
3minutes.
If the subject feels unable to stand, supine vital signs only will be recorded. 
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptom s.  Addit ional vital signs may be m easured during each study  period if 
warranted.
9.4.2.1. Ambulatory Blood Pressure Monitoring
For each subject , ABPM will be performed according to the Schedule of Activit ies (Secti on 2).
H8H-MC-LAIG Clinical Pharmacology Protocol Page 32
LY573144Site invest igativepersonnel shoul d be trained on the correct posit ioning of the ABPM monitor, 
use of correct cuff size, and mo nitor calibration prior to the start of the study .  Subjects s hould be
trained on the ABPM device on the evening of Day  -1to maximize the collection of valid 
measurements, and to alleviate any concerns about i nconvenience due to the con tinuous 24- hour 
monitoring.
The ABPM device shoul d be attached to the subject’s nondominant arm and will record 
ambulatory  BP and PR every  20minutes during awake hours ( e.g.0700 hours to 2200 hours) and 
every 30 minutes throughout the night (2200 hours to 0700 hours).  On D ays 1, 3, and 5 when 
dosing occurs, the BP and PR recording w ill be initiated approximately 2 hours prior to the 
planned dosing time and will cont inue for approximately 26 hours. Subjects will be encouraged 
to keep the same routine without strenuous activit y during the ABPM recording days.
The ABPM device should be removed from each subject prior to their discharge from the CRU.
9.4.3. Electrocardiograms
For each subject , ECGs should be collected according to the Schedule of Activit ies (Secti on2).
Any clinically  significant findings from ECGs that result in a diagnosis and that occur after the 
subject receives the first dose of the invest igational product should be reported to Lilly ,or its 
designee ,as an AE via eCRF.
For each subject , a single 12-lead digital ECG will be collected according to the Schedule of 
Activities(Secti on2).  Electrocardi ograms m ust be recorded before collecting any  blood 
samples .  Subjects must be supine for approximately  5 to 10 minutes before ECG collection and 
remain supine but awake during ECG collecti on.  Electrocardiograms may be obtained at 
additional times,when deemed clinically necessary.   All ECGs recorded should be stored at the 
investigat ional site.
Electrocardiograms will be interpreted by  
a qualified physician ( the investigator o r qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
subject is still present, to determine whether the subject meets entry criteria at the relevant 
visit(s) and for immediate subject management, sho uld any clinically relevant findings be 
ident ified.  
If a clinically significant finding is ident ified (including, but not limited to ,changes in 
QT/corrected QT interval from baseline) after enrollment, the invest igator will determine if the 
subject can continue in the study .  The invest igator ,or qualified designee ,is responsible for 
determining if any change in subject management is needed ,and must document his/her review 
of the ECG printed at the time of co llection.  Any  new clinically  relevant finding shoul d be 
reported as an AE.
9.4.4. Safety Monitoring
The Lilly CPor CRP /scientist will mo nitor safet y data throughout the course of the study .
H8H-MC-LAIG Clinical Pharmacology Protocol Page 33
LY573144Lilly will review SA Es wi thin time frames mandated by co mpany procedures.  The Lilly CPor 
CRP will periodically review the following data:
trends in safety  data
laboratory  analy tes
adverse events .
When appropriate, the Lilly CPor CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y therapeutic area physician or clinical research scient ist.
9.4.4.1. Hepatic Safety
If a study  subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or el evated total  
bilirubin ≥2X ULN, liver tests (Appendix 4 ) should be repeated within 3 to5 day s including 
ALT, AST, ALP, total bilirubin ( TBL ), direct bilirubin , gamma -glutamyl transferase, and 
creatinine kinase to confirm  the abnorm ality and to determine if it is increasing or decreasing.  If 
the abnormalit y persists or worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the 
investigator based on consultation with the Lilly CPor CRP .  Moni toring shoul d continue unt il 
levels norm alize and/or are return ingto approximate baseline levels.
Addit ional safet y data should be co llected if 1or more of  the f ollowing condit ions occur: 
elevation of serum  ALT to ≥5X ULN on 2 or more consecutive blood tests
elevation of serum  TBL to ≥2X ULN (except for cases of known Gilbert’s 
syndro me)
elevation of serum  ALP to ≥2X ULN on 2or more consecutive blood tests 
patient/subject di scontinued from treatment due to a hepat ic event or abnormali ty 
of liver tests
hepatic event considered to be a nSAE.
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities(Secti on2), venous blood samples 
of approximately 2mL each will be co llected to determine the plasma concentrations o f 
lasmiditan .
A maximum of 3samples m ay be collected at additional t ime po ints dur ing the study if 
warranted and agreed upon between both the investigator and sponsor.  Instructions for the 
collect ion and handling of blood samples will be provided by the sponsor.   The actual date and 
time (24
-hour clock time) of each sampling will be re corded.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a facilit y 
designated by  the sponsor .
H8H-MC-LAIG Clinical Pharmacology Protocol Page 34
LY573144Concentrations of lasmidi tan will be assayed using a validated liquid chro matography  with 
tandem  mass spectrometry method.  Analyses of samples collected from subjects who received 
placebo are not pl anned.
Bioanaly tical samples collected to m easure invest igational product concentrations will be 
retained for a maximum o f 1 year following l astsubject visit for the study .
9.6. Pharmacodynamic s
This sect ion is not applicable for this study .
9.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule of 
Activities(Secti on2), where local regulat ions allo w.
Samples willnot be used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response t o 
lasmiditan and to invest igate genet ic variants thought to play a role i n migraine .  Assessment of 
variable response may include evaluation of AEs or differences in efficacy .
All samples will be coded with the subject number.  These samples and any data generated can 
be linked back to the subject only by the invest igativesite personnel .
Samples will  be retained for a m aximum  of 15 y ears after the last subject visit, or for a shorter 
period if local regulat ionsand/or ERBs impose shorter time lim its, for the study  at a f acilit y 
selected by Lilly or i ts desi gnee .This retention period enables use of new techno logies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the devel opment of lasmiditan or after lasmidi tanis commercially available.
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, e xisting approaches include who le geno me or exome 
sequencing, geno me-wide associ ation studies, multiplex assays, and candidate gene studies .  
Regardless of techno logy utilized, data generated will be used only  for the specific research 
scope described in this sect ion
.
9.8. Biomarker s
This sect ion is not applicable for this study .
9.9. Health Economics
Thissection is not applicable for this study.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 35
LY57314410. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Up to 3 6subje cts m ay be enro lled to ensure 30 subjects complete the study .Assuming a 1-sided 
significance level of 0.05, a standard deviat ion for the within-subject change in SBP of 
6.0mmHg (a slight ly larger estimate than that seen in Study LAHA) ,and a noninferiorit y margin 
of 10 mmHg, this sample size will result in at least 90% power to detect a true increase of 
5mmHg in the mean within-subject change for lasmidi tan 200 m g com pared wi th placebo.
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description o fsubject disposit ion will be provided at the end of the study .
10.2.2. Study Participant C haracteristics
The subjects’ age, sex, weight, height, BMI, race, and other demographic characterist ics will be 
recorded and summarized using descript ive statist ics.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of EliLilly and Company  or its 
designee .
Cardi ovascular analyses will be conducted on data fro m subjects who complete at least 1 dosing 
period.
Pharmacokinet icanalyses will be conducted on data fro m all subjects who receiv eat least 1dose 
of the invest igational product sand have evaluable PK .
Pharmacokinet ic/pharmacodynamic analyses will be conducted on data from subjects who have 
evaluable data in both PK and cardio vascular datasets.
Safety analyses will be conducted for all enro lledsubjects ,whether or not they com pleted all  
protocol  requi rements.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  
10.3.1. Safety Analyses
10.3.1.1. Clinical Evaluation of Safety
All invest igational product and protocol procedure AEs will be listed, and if the frequency o f 
events allows, safet y data will be summarized using descript ive methodol ogy.
The incidence of symptoms for each treatment will be presented by  severi ty and by associ ation 
with invest igational product as perceived by the investigator.  Symptoms reported to occur prior 
toenrollment will be dist inguished fro m those reported as new or increased in severit y during the 
H8H-MC-LAIG Clinical Pharmacology Protocol Page 36
LY573144study .  Each symptom will be classified by the most suitable term fro m the Medical Dicti onary  
for Regulatory  Activit ies.
The number of invest igational product -related SAEs will be reported.
10.3.1.2. Statistical Evaluation of Safety
Safety param eters that will be assessed include safety  laboratory parameters , vital signs, DBP ,
and pulse rate obtained via ABPM, and AEs.  The param eters will  be listed, and summarized 
using standard descript ive statist ics.  Addi tional analysis will be performed if warranted upon 
review of the data.
10.3.2. Pharmacokinetic Analyses
10.3.2.1. Pharmacokinetic Paramete r Estimation
Pharmacokinet ic parameter estimates for lasmiditan will be calculated using standard 
nonco mpart mental methods of analysis.   The primary  param eters f or analysis will be C maxand 
AUC of lasmiditan .  Other noncom partm ental  parameters, such as hal f-life, apparent clearance, 
and apparent volume of distribution may be reported.
10.3.2.2. Pharmacokinetic Statistical Analysis
Theparam eters will  be listed, and summarized using standard descriptive statist ics, including
estimates of intra -subject variabilit yas appropri ate.
10.3.3. Cardiovascular Analyses
10.3.3.1. Cardiovascular Parameter Estimation
The primary  parameter sfor the cardi ovascular analyses will be peak hourly  mean values of SBP, 
and will be determined using ABPM.   For each subject, the mean SBP will be calculated for each 
hour wi thin the dosing period .  The highest mean value across the 24 calculated means will be 
considered the peak hourly mean value.   Baseline value will be defined as the mean value during 
the 2 hours pre -dose for each period.
10.3.3.2. Statistical Inference of Cardiovascular Parameters
Cardi ovascular parameters will  be listed, and summarized using descriptive statist ics, as 
appropriate.
As a primary analysis, c hanges from baseline in peak hourly mean values of SBP will be 
analyzed to test whether each dose o f lasmidi tan (100 m g, 200 m g) is noninferior to placebo, 
assuming a noninferiorit y margin o f 10 mmHg.  Specifically , these changes from  baseline will be 
analyzed to test thenull hypotheses th at the difference in mean baseline change between 
lasmiditan at each dose a nd placebo is at least 10 mmHg versus the alternat ive hypotheses that 
this difference is less than 10 mmHg .
A linear mixed -effects m odel with baseline as a covariate, fixed effects for treatment, period (1, 
2, or 3), and treatm ent sequence, and a rando m effect for subject will be used to test the
hypotheses at a 1-sided significance level o f 0.05. Least squares (LS) means and treatment 
H8H-MC-LAIG Clinical Pharmacology Protocol Page 37
LY573144differences (lasmiditan 200 mg –placebo, l asmidi tan 100 m g -placebo) will be calculated and 
presented with theircorresponding 95% CIs.
The fo llowing gatekeeping procedure will be used to adjust for mult iplicit y when conduct ingthe
hypothesis tests.  The null hypothesis that the difference in mean baseline change between 
lasmiditan 100mg and placebo is at leas t 10 mmHg will first be tested against the alternat ive 
hypothesis that this difference is less than 10 mmHg.   If the p-value for this test is less than 0.05, 
then there is significant evidence that lasmiditan 100 mg is non-inferior to placebo and these 
hypotheses will be re-tested using lasmiditan 200 mg.  O therwise, if the p -value is at least 0.05, 
then there is no significant evidence that lasmiditan 1 00 m gis noninferior to placebo, in which 
case the null and alternat ive hypotheses will not be re -tested using lasmiditan 200 mg
.
A sensit ivity analysis will be performed on subject s who complete all 3 dosing peri ods. The 
same mixed -effects modelas that was used in the primary  analysis will be implemented.
A repeated measures analysis will also be conducted in which changes from baseline in hourly 
mean values o f SBP will be analyzed to test whether each dose of lasmiditan (100 mg, 200 mg) 
is noninferior to placebo at each time point (hour) , assuming a noninferiorit y margin o f 10 
mmHg.  A repeated measures linear mixed -effects model with baseline as a covariate, fixed 
effects for time po int, treatment, period, treatment sequence, and the treatment by t ime point
interact ion, and a rando m effect for subject will be used to conduct thetests at a 1-sided 
significance l evel of 0.05 .  At each time po int, LS means and treatment differences (lasmiditan 
200 m g 
–placebo, l asmidi tan 100mg –placebo) will  be calculated and presented with the ir
corresponding 95% CIs, from which noninferiorit y of lasmiditan (100 mg, 200 mg) to placebo 
will be determined if the upper confidence limit is less than 10 mmHg.
10.3.4. Pharmacokinetic/Pharmacodynamic Analyses
The rel ationship between PK and cardi ovascular effects will be explored init ially in a graphical 
manner .  Addit ionalmodeling ap proaches or graphical analyses may  be used, if warranted.
10.3.5. Interim Analyses
No interim analyses are planned for this study .  If an unplanned interim analysis is deemed 
necessary , the Lilly CP, CRP /investigator, or designee will consult with the appropriate medical 
director or desi gnee to determine if it is necessary  to am end the protocol .
H8H-MC-LAIG Clinical Pharmacology Protocol Page 38
LY57314411. References
Färkkilä M, Diener HC, Géraud G, Láinez M, Schoenen J, Harner N, Pilgrim A, Reuter U; COL 
MIG -202 S tudy Group. Efficacy  and tol erabilit y of lasmiditan, an oral 5 -HT(1F) receptor 
agonist, for the acute treatment of migraine: a phase 2 randomised, placebo -controlled, 
parallel- group, dose -ranging study . Lancet Neurol . 2012;11(5):405 -413.
Victor TW, Hu X, Campbel l JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in 
the United States: a life span study . Cephalalgia . 2010;30(9):1065 -1072.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 39
LY573144Appendix 1. Abbreviations and Definitions
H8H-MC-LAIG Clinical Pharmacology Protocol Page 40
LY573144Term Definition
5-HT 5-hydroxy tryptamine
ABPM ambulatory blood pressure monitoring
ACE angiotensin -converting enzyme 
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product .
ALP alkaline phosphatase
ALT alanine aminotransferase
ARB angiotensin receptor blocker
AST aspartate aminotransferase
AUC area under the concentration versus time curve
blinding A procedure in which 1or more parties to the study are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the subject is no t, or vice versa, or when the sponsor is aware of the treatment 
but the investigator and/his staff and the subject are not. A double -blind study  is one in 
which neither the subject nor any of the investigator or sponsor staff who are involved in 
the treat ment or clinical evaluation of the subjects are aware of the treatment received .
BMI body mass index
BP blood pressure
CI confidence interval
Cmax maxi mum observed drug concentration
CNS central nervous system
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 41
LY573144confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that L illy is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be re -tested at some defined time point, depending on the steps required to obtain 
confirmed results.
CP clinical pharmacologist
CRP clinical research physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician ,or other medical of ficer.
CRU clinical research unit
CYP cytochrome P450
DBP diastolic blood pressure
eCRF electronic case report form
enroll The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment.
ERB ethical review board
GCP good clinical practice
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonization
informed consent A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular study , after having been informed of all aspects of the study that are relevant to 
thesubject ’s decision to participate. Informed consent is documente d by means of a 
written, signed, and dated informed consent form .  
investigational 
productApharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical study, including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator A person respon sible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
legal 
representativeAn in dividual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject , to the subject ’s participation in the clinical study.
LS least squares
H8H-MC-LAIG Clinical Pharmacology Protocol Page 42
LY573144PK pharmacokinetic (s)
PPI protein pump inhibitor
PR pulse rate
randomize The process of assigning subjects/ patients to an experimental group on a random basis .
SAE serious adverse event
SBP systolic blood pressure
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .  
SUSAR suspected unexpected serious adverse reaction
TBL total bilirubin
TEAE treatment -emergent adverse event :  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state ,anddoes not necessarily have to have a causal relationship with this 
treatment 
tmax time of maximum observed drug concentration
ULN upper limit of normal
H8H-MC-LAIG Clinical Pharmacology Protocol Page 43
LY573144Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Total CO 2
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phospho rus
Leukocytes (WBC) Glucose random
Platelets Blood urea nitrogen (BUN)
Differential WBC absolute counts and/or % of: Total protein
Neutrophils Albumin
Lymphocy tes Total bilirubin
Monocytes Alkaline phosphatase (ALP)
Eosinophils Aspartate aminotransferase (AST)
Basophils Alanine aminotransferase (ALT)
Urinaly sis Creatinine
Specific gravity Ethanol testing a
pH Urine drug screen a,b
Protein Hepatitis B surface antigen b
Glucose Hepatitis C antibody b
Ketones HIV b
Bilirubin FSH c
Urobilinogen
Blood
Nitrite
Leukocytes 
Urine microscopic (if positive result for blood)
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus; RBC = red blood cell; 
WBC = white blood cell.
aPerformed on admission.
bPerformed at screening.
cPerformed at screening only for confirmation of postmenopausal status.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 44
LY573144Appendix 3. Study  Governance, Regulatory ,and 
Ethical Considerations
Informed Consent
The invest igator is responsible for
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary.
ensuring that informed consent is given by each subjec t or l egal representative.  Thi s 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of invest igational 
product.
answering any quest ions the subject may  havethroughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the subject ’swillingness to 
continue his or her participat ion in the study .
provi ding a copy  of the ICF to the parti cipant or the participant’s legal represen tative and 
retaining a copy  on file .
Ethical Review
The invest igator or appropriate local representative must give assurance that the ERB was 
properly const ituted and convened as required by Internat ional Council for Harmonizat ion (ICH)
guidelines and othe r applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must b e com pliant wi th the ICH gui deline 
on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF 
relevant curri cula vi tae
Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences Internat ional Ethical Guidelines 
2)applicable ICH GCP Guidelines 
H8H-MC-LAIG Clinical Pharmacology Protocol Page 45
LY5731443)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party  organi zation.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the b est 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly repres entative.
Final Report Signature
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical o fficer and statistician wil l sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable dat a, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate.
provi detraining to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the compl etion of the CRFs, and study  procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax.
review and evaluate CRF data and/or use standard computer edits to detect errors in data 
collect ion.
conduct a qualit y review of the database .
In addit ion, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study  site.  The study  may be audi ted by Lilly and/or 
regul atory  agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original source 
docum ents.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 46
LY573144Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study . The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordanc e with local 
data protecti on law.
The p urpose and use of subject/patient personal information co llected will be provided in a 
written docum ent to the subject/patient by  the sponsor .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipation m ay be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly or i ts desi gnee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
H8H-MC-LAIG Clinical Pharmacology Protocol Page 47
LY573144Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests may be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with Lilly or i ts desi gnee CRP .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin time
WBC Prothrombin time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear Antibody a
AST Alkaline Phosphatase Isoenzymes a
GGT
CPK Anti -smooth Muscle Antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/c onfirmation dependent on regulatory requirements and/or testing availability .
H8H-MC-LAIG Clinical Pharmacology Protocol Page 48
LY573144Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .
Protoco l H8H -MC -LAIG Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 19.5 1 19.5
Clinical laboratory tests a 12.5 2 25
Pharmacokinetics 2 40 80
Pharmacogenetics 10 1 10
Total 134.5
Total for clinical purposes rounded up to the nearest 10 mL 140
aAdditional samples may be drawn if needed for safety purposes.
Leo Document ID = 502f8e55-244d-4fd3-a3b6-6adc0b36f2ca
Approver:
Approval Date & Time: 19-Dec-2017 16:58:13 GMT
Signature meaning: Approved
Approver:
Approval Date & Time: 19-Dec-2017 17:01:03 GMT
Signature meaning: Approved
PPD
PPD